Alzheimer Disease CME - Course Details

Assessing Current Practice in Alzheimer's Disease Baltimore Marriott Waterfront, Baltimore, Md - February 24, 2004

Target Audience

Physicians (MD, DO, or equivalent),
physician assistants

Release Date

June 2004

Termination Date

June 2005

Estimated Completion Time

2 hours

Chairperson

Jacobo E. Mintzer, MD
Professor of Psychiatry, Neurology, Physiology, and Neuroscience
Medical University of South Carolina

Faculty

Michael A. Rogawski, MD, PhD
Senior Investigator
Chief of Epilepsy Research Section
National Institute of Neurological Disorders and Stroke
National Institutes of Health

Mary Sano, PhD
Professor of Psychiatry
Mount Sinai School of Medicine
Director of Research
Bronx Veterans Administration Hospital

Gary W. Small, MD
Parlow Solomon Professor of Aging
Professor of Psychiatric and Biobehavioral Sciences
Director of the Aging and Memory Research Center and
Memory Clinic at the Neuropsychiatric Institute
University of California at Los Angeles

Christopher H. van Dyck, MD
Associate Professor of Psychiatry and Neurobiology
Yale University School of Medicine

This interactive series of free CME courses is based on presentations recently given at cutting-edge national seminars and meetings by experts in the fields of Alzheimer's disease and dementia in general. These exciting new courses include multimedia slides, audio, video, and animations and provide up-to-date information on the evaluation, diagnosis, and treatment of Alzheimer's disease. All courses are accredited for up to 2 hours of AMA PRA category 1 credit.

Faculty Disclosures for the Proceeding of the Symposium in Baltimore

Jacobo E. Mintzer, MD, is a consultant for Abbott, AstraZeneca, Eli Lilly, Bristol Myers Squibb, Capital Research Company, the Council of Healthcare Advisors, Forest Laboratories, and UCB Pharma. He also receives grants and research support from Abbott, the Alzheimer's Disease Cooperative Study, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eisai America, Forest Laboratories, the Fujisawa Institute of America, Lilly Research Laboratories, Janssen Research Foundation, Johnson & Johnson, Mitsubishi, the National Institute on Aging, the National Institute of Mental Health, Novartis Pharmaceuticals, Parke-Davis, Pfizer, Sanofi-Synthelabo, Somerset Pharmaceuticals, SmithKline Beecham, and Wyeth-Ayerst Research. Dr Mintzer is on the speakers bureau for Abbott, AstraZeneca, Eisai America, Eli Lilly, Janssen Pharmaceutica, and Pfizer.

Michael A. Rogawski, MD, PhD, has previously served as a consultant for the Forest Research Institute.

Mary Sano, PhD, is a consultant for Forest Laboratories, Janssen Pharmaceutica, and Pfizer.

Gary W. Small, MD, is a consultant for Abbott, Amersham, AstraZeneca, CTI Molecular Imaging, Dakim, Eisai, Forest Laboratories, GIaxoSmithKline, Janssen Pharmaceutica, Lilly, Merck, MR, Novartis Pharmaceuticals, Organon, PET/NeT, Pfizer, and Roche.

Christopher H. van Dyck, MD, is a consultant for Forest Laboratories. He serves on a speakers bureau for Forest Laboratories and receives grant support from Forest Laboratories, Pfizer, and Janssen Pharmaceutica.

Course Objectives

After taking this course, participants will be better able to do the following:

• Evaluate practical approaches that can assist with detection and diagnosis of AD
• Critically analyze advances in brain imaging and what these techniques add to the management of AD
• Review the rationale for emerging pharmacologic treatment strategies for AD
• Discuss the latest advances in pharmacologic and nonpharmacologic treatment interventions for AD and how these should be best applied to daily clinical practice

Instructions to Participants

Course participants will view slide/audio presentations and then must successfully complete a test in order to receive CME credit. Full instructions are available on the course navigation page.

Continuing Medical Education Credit The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education activities. The AAGP designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. Disclaimer The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients. Medicine is a constantly changing science, and clearly established therapies are not always availablefor every condition. New research findings necessitate continual changes in drug and treatment therapies. The authors, editors, and publisher of this journal have used reasonable efforts to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the authors, editors, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, nor are they responsible for omissions, errors, or the results of using this information. The reader should confirm the accuracy of the information in this article from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts.

Click here to view minimum system requirements.